Study for advanced solid cancers with a DNA repair target
Part of Cancer clinical trials.
This Phase I/II trial tests an investigational treatment in people with advanced solid tumors that have grown despite standard therapy, or where standard options aren’t available. In later Phase II, the trial mainly enrolls patients whose tumor shows a specific DNA repair problem (DDR defect).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18–70 and sign consent to follow the study plan
- Have an advanced solid tumor confirmed by tumor biopsy/cell test, and it must have progressed on standard treatment (or no suitable standard treatment exists)
- Have a measurable tumor spot for Phase II (or assessable-only lesions may be allowed in Phase I at the doctor’s judgment)
- Be in good enough physical condition (ECOG 0 or 1) and expected to live at least 12 weeks
- Have safe heart rhythm and blood/organ tests: QTcF under 450 ms, adequate blood counts, and kidney/liver/clotting levels within required ranges
- Women who can become pregnant and men able to father a child must use effective birth control during treatment and for 3 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, TCC1727, combined with other treatments for people with advanced solid tumors that have stopped responding to standard therapy. It aims to see if these combinations can help shrink or control the cancer.
This study tests an experimental pill (DAT-2645) for people with advanced or metastatic solid tumors that have DNA repair problems, such as BRCA gene mutations. The drug targets a repair mechanism that these cancer cells need, potentially slowing or stopping their growth.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
This Phase 1 trial tests how safe and effective two anti-cancer drugs (peposertib and tuvusertib) are for advanced solid tumors. It focuses on cancers with specific DNA repair and cell-growth gene changes, aiming to shrink tumors and improve outcomes when standard treatments have stopped working.
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
Hear when a new Patients With Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.